firmonertinib
firmonertinib: developed by 1 company · 2 clinical trials tracked.
firmonertinib evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could firmonertinib → AVBP affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ArriVent BioPharma, Inc. (AVBP) Non-Small-Cell Lung Cancer; NSCLC | Phase 3 |
Clinical Trials (2)
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)
Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR)
A Global Phase 3, Double-Blind, Randomized, Controlled Multicenter Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy (FIRMOST)
Primary endpoint: Disease free survival (DFS)
Frequently asked questions
Who is developing firmonertinib?
firmonertinib is being developed by ArriVent BioPharma, Inc..
How many clinical trials involve firmonertinib?
BioSniper tracks 2 clinical trials involving firmonertinib.